Abbott Laboratories
ABT Healthcare Medical - Devices NYSE
$91.13
$-1.35 (-1.46%)
Open: $92.15 | High: $92.65 | Low: $91.05 | Prev Close: Prev Close: $92.48
Market Cap: $158.36B
Volume: 10.0M | Avg: 13.9M
Last updated: April 24, 2026 at 08:00 PMInvestment Rating
Sell
Overall Score: 40/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 555
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 25.53 |
| P/B Ratio | 3.05 |
| P/S Ratio | 3.51 |
| EPS | $3.57 |
| Beta | 0.78 |
| Shares Outstanding | 1.74B |
| 52-Week High | $139.06 |
| 52-Week Low | $90.72 |
| SMA 50 | $106.58 |
| SMA 200 | $121.77 |
| Dividend Yield | 2.68% |
| Annual Dividend | $2.44 |
| Next Earnings | July 16, 2026 12:30 PM ET |
Financial Ratios
| Gross Margin | 56.4% |
| Operating Margin | 18.2% |
| Net Margin | 13.9% |
| ROE | 12.4% |
| ROA | 7.2% |
| Debt/Equity | 0.29 |
| Current Ratio | 1.58 |
| Quick Ratio | 1.18 |
Balance Sheet
| Total Assets | $86.71B |
| Total Liabilities | $33.94B |
| Total Equity | $52.13B |
|
|
|
| Cash | $8.52B |
| Total Debt | $15.07B |
| Net Debt | $6.54B |
Income Statement
| Revenue | $44.33B |
| Gross Profit | $24.61B |
| Operating Income | $8.05B |
| Net Income | $6.52B |
|
|
|
| EBITDA | $11.55B |
| Revenue/Share | $25.84 |
Cash Flow
| Operating CF | $9.57B |
| CapEx | $2.17B |
| Free Cash Flow | $7.39B |
|
|
|
| Book Value/Share | $30.21 |
| Tangible Book/Share | $13.29 |
| Equity/Share | $29.84 |
Technical Indicators
| RSI (14) | 19.52 Oversold |
| MACD |
-3.83
Signal: -3.19
|
| Volatility | 21.32% |
| Trading Signal | Oversold |
Performance & Returns
| 1 Year | -31.59% |
| Sharpe Ratio | -2.07 Poor |
| Volatility (Ann.) | 23.54% Moderate |
| ABT (1Y) | -31.59% |
| S&P 500 (1Y) | +14.41% |
| Alpha (Excess Return) | -46.0% |
Sector Comparison (Healthcare)
| Metric | ABT | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 25.53 | 26.25 | 52% |
| P/B Ratio | 3.05 | -21.08 | 52% |
| ROE (%) | 12.40% | -10.14% | 46% |
| Net Margin (%) | 13.91% | 9.35% | 56% |
| Stock Score | 555 | 548.0 | 44% |
| 1Y Return (%) | -31.59 % | +5.91 % | 8% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABT | $91.13 | $93.88 | $95.52 | $97.87 | $106.40 | $121.61 | 19.52 | -3.83 | 21.32% | 651337 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the ABT stock
News Sentiment
| Ticker | Headline | Sentiment | Source | URL |
|---|---|---|---|---|
| ABT | Abbott Laboratories $ABT Shares Purchased by Advisors Capital Management LLC | Neutral | defenseworld.net | Read More |
| ABT | Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026 | Neutral | prnewswire.com | Read More |
| ABT | Best Dividend Kings: April 2026 | Neutral | seekingalpha.com | Read More |
| ABT | Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet | Neutral | zacks.com | Read More |
| ABT | Abbott Laboratories: Buying A Healthcare Giant On Sale | Neutral | seekingalpha.com | Read More |
Recent Insider Trading
No recent insider trading data available for ABT
Company Information
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
| CEO | Robert Ford |
| Employees | 114000 |
| Country | US |
| IPO Date | 1980-03-17 |
| Exchange | NYSE |
| Website | https://www.abbott.com |
| Sector | Healthcare |
| Industry | Medical - Devices |
Similar Stocks (Healthcare - Medical - Devices)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category